{"id":"W2015395716","doi":"10.1007/s10637-013-0024-y","title":"Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; University of California, Davis; Celgene; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Paclitaxel; Progressive disease; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001144657,0.001775047,0.002296892,0.0004931657,0.0005086496,0.001276749,0.00100043,0.001353322,0.005657156],"category_scores_gemma":[0.000865936,0.0006384504,0.001474719,0.0004469742,0.001227684,0.001350142,0.0004414018,0.003920261,0.001076859],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001254456,"about_ca_system_score_gemma":0.001494731,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001650078,"about_ca_topic_score_gemma":0.004087911,"domain_scores_codex":[0.9996989,0.0001252909,0.00001103694,0.00006501739,0.00001645671,0.00008328645],"domain_scores_gemma":[0.9994816,0.0000839565,0.00006716411,0.00004109836,0.00002327847,0.0003029205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8845606,0.03588695,0.00230587,0.0005105214,0.001093876,0.0001589043,0.0001943708,0.003086941,0.01499756,0.0004223066,0.004028147,0.05275393],"study_design_scores_gemma":[0.7991477,0.1912287,0.004352961,0.00002866335,0.0003579861,0.0001225531,0.0000697489,0.00105319,0.001385063,0.0002827051,0.001950336,0.00002046045],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880874,0.002501024,0.0005207368,0.001410808,0.000386178,0.002107175,0.001516652,0.0001142919,0.003355713],"genre_scores_gemma":[0.9831508,0.002834206,0.001487205,0.001326624,0.0002935067,0.002306558,0.002793568,0.00005166176,0.00575592],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005657156,"threshold_uncertainty_score":0.01892513,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01173629540340306,"score_gpt":0.3110161216133163,"score_spread":0.2992798262099132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}